Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
Rapid Micro Biosystems (Nasdaq: RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, has scheduled its first quarter 2025 financial results announcement for May 9, 2025, before market opening.
The company will host a webcast conference call at 8:30 a.m. ET on the same day, with management discussing the results. The webcast will be available on the company's website and archived for future reference.
Rapid Micro Biosystems (Nasdaq: RPID), un'azienda tecnologica nel settore delle scienze della vita specializzata in soluzioni di automazione per la produzione di prodotti sanitari, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 9 maggio 2025, prima dell'apertura dei mercati.
Lo stesso giorno, alle 8:30 a.m. ET, la società terrà una teleconferenza webcast durante la quale il management discuterà i risultati. Il webcast sarà disponibile sul sito web dell'azienda e archiviato per consultazioni future.
Rapid Micro Biosystems (Nasdaq: RPID), una empresa tecnológica en ciencias de la vida especializada en soluciones de automatización para la fabricación de productos sanitarios, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 9 de mayo de 2025, antes de la apertura del mercado.
La compañía realizará una llamada conferencia vía webcast el mismo día a las 8:30 a.m. ET, donde la dirección discutirá los resultados. El webcast estará disponible en el sitio web de la empresa y se archivará para futuras consultas.
Rapid Micro Biosystems (나스닥: RPID)는 의료 제품 제조 자동화 솔루션을 전문으로 하는 생명과학 기술 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 9일 시장 개장 전으로 예정했습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 경영진이 결과를 논의하는 웹캐스트 컨퍼런스 콜을 진행할 예정입니다. 웹캐스트는 회사 웹사이트에서 시청 가능하며 추후 참고를 위해 아카이브됩니다.
Rapid Micro Biosystems (Nasdaq : RPID), une entreprise technologique en sciences de la vie spécialisée dans les solutions d'automatisation pour la fabrication de produits de santé, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 9 mai 2025, avant l'ouverture des marchés.
Le même jour, à 8h30 ET, la société tiendra une conférence téléphonique en webcast au cours de laquelle la direction commentera les résultats. Le webcast sera disponible sur le site web de l'entreprise et archivé pour une consultation ultérieure.
Rapid Micro Biosystems (Nasdaq: RPID), ein Unternehmen für Life-Science-Technologie, das sich auf Automatisierungslösungen für die Herstellung von Gesundheitsprodukten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 9. Mai 2025 vor Markteröffnung geplant.
Am selben Tag findet um 8:30 Uhr ET eine Webcast-Konferenzschaltung statt, bei der das Management die Ergebnisse erläutert. Der Webcast wird auf der Unternehmenswebsite verfügbar sein und für spätere Referenz archiviert.
- None.
- None.
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2025 financial results prior to the market open on Friday, May 9, 2025.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Friday, May 9, 2025. The live audio webcast will be accessible on the Company’s website and can be accessed with this link. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) release Q1 2025 earnings?
What time is RPID's Q1 2025 earnings conference call?
How can investors access RPID's Q1 2025 earnings call?
What does Rapid Micro Biosystems (RPID) specialize in?
